Main menu

Publications

Publications with relation to the UROMOL project:

 

1. Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.Cancer Res. 2009 Jun 1;69(11):4851-60.

2. Zieger K, Marcussen N, Borre M, Orntoft TF, Dyrskjøt L. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirms the presence of two major pathways in bladder cancer development. Int J Cancer. 2009 Nov 1;125(9):2095-103.

3. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, Ulhøi B, Borre M, Kjems J, Dyrskjøt L, Orntoft TF. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene. Published on line, 2009 Nov 16.

4. Rodríguez-Santiago B, Malats N*, Rothman N*, Armengol L, García-Closas M, Kogevinas M, Villa O, Hutchinson A, Earl J, Marenne G, Jacobs K, Rico D, Tardón A, Carrato A, Thomas G, Valencia A, Silverman, Real FX**, Chanock SJ**, Pérez-Jurado L**. Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. Am J Hum Genet 2010; 87:129-138.

5. Hafner C,* Toll A,* Fernández-Casado A, ** Earl J,** Marqués M, Acquadro F, Méndez-Pertuz M, Urioste M, Malats N, E Burns JE, Knowles M, Cigudosa JC, Hartmann A, Vogt T, Landthaler M, M. Pujol RM, Real FX. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA 2010; 107:20780-20785. Editorial Comment on this manuscript

6. Cantor KP, Villanueva CM, Silverman D, Figueroa JD, Real FX, Garcia-Closas M, Malats N, Chanock S, Yeager M, Tardon A, Garcia-Closas R, Serra C, Carrato A, Castaño-Vinyals G, Samanic C, Rothman N, Kogevinas M. Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection byproducts, and risk of bladder cancer in Spain. Environ Health Persp 2010; 118:1545-1550.

7. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M,Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R,Serra C, Silverman DT, Chanock S, Real FX, Malats N. Genetic Susceptibility to Distinct Bladder Cancer Subphenotypes. Eur Urol. 2010 Feb;57(2):283-92.

8. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011 Mar 15;128(6):1327-34.

9. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Real FX, ... , Silverman DT, Chanock S. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010 Nov;42(11):978-84.

10. Brems-Eskildsen AS, Zieger K, Toldbod H, Holcomb C, Higuchi R, Mansilla F, Munksgaard PP, Borre M, Orntoft TF, Dyrskjot L. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer. 2010 Nov 24;10:646.

11. García-Closas M, Hein DW, Silverman D, Malats N, Yeager M, Jacobs K, Doll MA, Figueroa JD, Baris D, Schwenn M, Kogevinas M, Johnson A, Chatterjee N, Moore LE, Moeller T, Real FX, Chanock S, Rothman N. A single nucleotide polymorphism identified in a genome-wide scan tags variation in the N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 2011; 21:231-236.

12. Marenne G, Rodríguez-Santiago B, García-Closas M, Pérez-Jurado L, Rothman N, Rico D, Pita G, Pisano DG, Kogevinas M, Silverman DT, Valencia A, Real FX, Chanock S, Génin E, Malats N. Assessment of copy number variation using the Illumina Infinium 1M SNP-array: A comparison of methodological approaches in the Spanish Bladder Cancer/EPICURO Study. Human Mut 2011; 32:240-248.

13. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF Jr, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011; 20:4282-4289.

14. Menashe I, Figueroa J, Garcia-Closas M, Chatterjee N, Malats N, Picornell A, Dennis M, Qi Y, Prokunina-Olsson L, Wang Z, Real FX, Jacobs KB, Baris D, Thun M, Demetrius Albanes D, Purdue MP, Kogevinas MK, Hutchinson A, Fu YP, Tang W, Burdette L, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Schned A, Andriole G , Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J1 Caporaso N, Landi MT, Fraumeni JF, Chanock SJ, Silverman DT, Rothman N. Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. PLoS ONE 2011; 7:e29396.

15. Hafner C, Toll A, Real FX. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. N Eng J Med 2011; 365:1940-1942.

16. Nordentoft I, Dyrskjot L, Bodker JS, Wild PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF, Birkenkamp-Demtroder K. Increased expression of Transcription Factor TFAP2 alpha correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. BMC Cancer. 2011 Apr 14;11:135.

17. Jensen JB, Munksgaard PP, Sørensen CM, Fristrup N, Birkenkamp-Demtroder K, Ulhøi BP, Jensen KM, Orntoft TF, Dyrskjøt L. High Expression of Karyopherin-α2 Defines Poor Prognosis in Non-Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy. Eur Urol. 2011 May;59(5):841-8.

18. Zuiverloon TC, Tjin SS, Busstra M, Bangma CH, Boeve ER, Zwarthoff EC: Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. J Urol. 2011 Aug;186(2):707-12.

19. Thomas Reinert, Charlotte Modin, Philippe Lamy , Tomasz K Wojdacz, Lise Lotte Hansen, Carsten Wiuf, Michael Borre, Lars Dyrskjøt, Torben F. Ørntoft. Comprehensive genome methylation analysis in bladder cancer; identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011 Sep 1;17(17):5582-92.

20. Pia Pinholt Munksgaard, Francisco Mansilla, Anne-Sofie Brems Eskildsen, Niels Fristrup, Karin Birkenkamp-Demtrøder, Benedicte Parm Ulhøi, Michael Borre, Mads Agerbæk, Gregers G. Hermann, Torben F. Ørntoft and Lars Dyrskjøt. Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer. 2011 Oct 25;105(9):1379-87.

21. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. International Journal of Cancer. 2011;128(6):1327-1334.

22. Sune B Villadsen, Jesper B Bramsen, Marie S Ostenfeld, Erik D Wiklund , Niels Fristrup, Shan Gao, Thomas B Hansen, Trine I Jensen, Michael Borre, Peter A Andreasen, Torben F Ørntoft, Lars Dyrskjøt and Jørgen Kjems. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2012 Jan 17;106(2):366-74.

23. Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, Zwarthoff EC. Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers. European urology. 2012 Jan 18.

24. van Tilborg AA, Kompier LC, Lurkin I, Poort R, El Bouazzaoui S, van der Keur K, Zuiverloon T, Dyrskjot L, Orntoft TF, Roobol MJ, Zwarthoff EC. Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. PLoS One. 2012;7(8):e43345.

25. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, Eijkemans MJ, Schouten JP, Zwarthoff EC: A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 2012 Mar;109(6):941-8.

26. Niels Fristrup, Benedicte Parm Ulhøi, Karin Birkenkamp-Demtröder, Francisco Mansilla, Marta Sanchez-Carbayo, Ulrika Segersten, Per-Uno Malmström, Arndt Hartmann, Joan Palou, Miguel Alvarez-Múgica, Michael Borre, Torben F. Ørntoft, and Lars Dyrskjøt. Cathepsin E, Maspin, PLK1, and Survivin are prognostic protein markers for progression in non-muscle invasive bladder cancer - a large scale tissue microarray validation study. Am J Pathol. 2012 Mar 23. [Epub ahead of print].

27. Hafner C*, Toll A*, Gantner S, Mauerer A, Lurkin I, Acquadro F, Fernández-Casado A, Zwarthoff EC, Dietmaier W, Baselga E, Parera ME, Vicente MA, Casanova AE, Cigudosa JC, Mentzel T, Pujol RM, Landthaler M, Real FX. Mosaic RAS mutations are associated with keratinocytic epidermal nevi. J Med Genet 2012; 49:249-253.

28. Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y, Malats N, Tang W, Liu L, Garcia-Closas M, Muchmore B, Chatterjee N, Tarway M, Kogevinas M, Porter-Gill P, Baris D, Mumy A, Albanes D, Purdue MP, Hutchinson A, Carrato A, Tardón A, Serra A, Garcia-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Diver WR, Gapstur SM, Thun M, Virtamo J, Chanock SJ, Fraumeni JF, Silverman DT, Wu X, Real FX, Prokunina-Olsson L. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci USA 2012; 109:4974-4979 .

29. Jacobs KB, Yeager M, et al. .... Real FX, Fraumeni JF, Caporaso NE, Tucker M, Rothman N, Perez-Jurado L, Chanock SJ (a total of 189 authors). Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012; 44:651-658.

30. Christiansen A, Dyrskjot L. The functional role of the novel biomarker karyopherin alpha 2 (KPNA2) in cancer. Cancer Lett. 2013;331(1):18-23. Epub 2012/12/27.

31. Fristrup N, Birkenkamp-Demtroder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmstrom PU, Palou J, Alvarez-Mugica M, Pan CC, Ulhoi BP, Borre M, Orntoft TF, Dyrskjot L. Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle Invasive Bladder Cancer. Am J Pathol. 2012.

32. Reinert T, Borre M, Christiansen A, Hermann GG, Orntoft TF, Dyrskjot L. Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation. PLoS One. 2012;7(10):e46297. Epub 2012/10/12.

33. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhoi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rodel C, Borre M, Jensen JB, Orntoft T, Dyrskjot L. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int. 2012. Epub 2012/10/11.

34. Dyrskjot L, Reinert T, Novoradovsky A, Zuiverloon TC, Beukers W, Zwarthoff E, Malats N, Real FX, Segersten U, Malmstrom PU, Knowles M, Hurst C, Sorge J, Borre M, Orntoft TF. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br J Cancer. 2012. Epub 2012/09/15.

35. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Orntoft TF, Dyrskjot L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 2012;5(1):40. Epub 2012/09/08.

36. Schepeler T, Lamy P, Laurberg JR, Fristrup N, Reinert T, Bartkova J, Tropia L, Bartek J, Halazonetis TD, Pan CC, Borre M, Dyrskjot L, Orntoft TF. A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response. Oncogene. 2012. Epub 2012/08/29.

37. Dyrskjot L, Zieger K, Kissow Lildal T, Reinert T, Gruselle O, Coche T, Borre M, Orntoft TF. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer. 2012. Epub 2012/05/19.

38. Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmstrom PU, Hartmann A, Palou J, Alvarez-Mugica M, Zieger K, Borre M, Orntoft TF, Dyrskjot L. Cathepsin e, maspin, plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012;180(5):1824-1834. Epub 2012/03/28.

39. Maniecki MB, Etzerodt A, Ulhoi BP, Steiniche T, Borre M, Dyrskjot L, Orntoft TF, Moestrup SK, Moller HJ. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012. Epub 2012/03/01.

40. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Orntoft TF, Dyrskjot L, Kjems J. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. British Journal of Cancer. 2012;106(2):366-374.

41. Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A, Domínguez O, Pisano DG, Gómez G, Lloreta J, Lorente JA, Malats N, Real FX. ARID1A alterations are associated with FGFR3 wild type, poor-prognosis, urothelial bladder tumors. PLoS ONE 2013;8:e62483. doi:10.1371/journal.pone.0062483.

42. Allory Y,* Beukers W,* Sagrera A, Flandez M, Marques M, Marquez M, van der Keur A, Dyrskjot L, Lurkin I, Vermej M, Carrato A, Lloreta J, Lorente JA, Carrillo-de-Santa-Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AAG, Abas C, Orntoft TF, Zuiverloon TCM, Malats N, Zwarthoff EC,** Real FX.** TERT promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2013; In press.

43. Balbás-Martínez C, Sagrera A*, Carrillo-de-Santa-Pau E*, Earl J, Márquez M, Vázquez M, Lapi E, Castro-Giner F, Beltrán S, Bayés M, Carrato A, Cigudosa JC, Domínguez O, Gut M, Herranz J, Juanpere N, Kogevinas M, Langa X, López-Knowles E, Lorente JA, Lloreta J, Pisano DG, Richart L, Rico D, Salgado RN, Tardón A, Chanock S, Heath S, Valencia A, Losada A, Gut I, Malats N, Real FX. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013; In press.

44. Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, Papafotiou G, Hodny Z, Sosa-Pineda B, Wu XR, Klinakis A, Orntoft T, Lukas J, Bartek J, Gorgoulis VG. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ. 2013.

45. Tajuddin SM, Amaral AF, Fernández AF, Rodríguez-Rodero S, Rodríguez RM, Moore LE, Tardón A, Carrato A, García-Closas M, Silverman DT, Jackson BP, García-Closas R, Cook AL, Cantor KP, Chanock S, Kogevinas M, Rothman N, Real FX, Fraga MF, Malats N; Spanish Bladder Cancer/EPICURO Study Investigators. Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA. Environ Health Perspect. 2013 Jun;121(6):650-6. doi: 10.1289/ehp.1206068. Epub 2013 Apr 1. PubMed PMID: 23552396; PubMed Central PMCID: PMC3672919.

46. Czachorowski MJ, Amaral AF, Montes-Moreno S, Lloreta J, Carrato A, Tardón A, Morente MM, Kogevinas M, Real FX, Malats N; SBC/EPICURO investigators. Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. PLoS One. 2012;7(9):e45025. doi: 10.1371/journal.pone.0045025. Epub 2012 Sep 13. PubMed PMID: 23028744; PubMed Central PMCID: PMC3441520.

47. W. Beukers, R. Kandimalla, D. van Houwelingen1, H. Kovacic1, J.F. D. Chin1, H. F. Lingsma2, l. Dyrskjot3, Ellen C. Zwarthoff1, The use of molecular analyses in voided urine for the assessment of patients with hematuria, Accepted Plos One 2013

48. Kandimalla R, Masius R, Beukers W, Bangma CH, Orntoft TF, Dyrskjot L, Leeuwen NV, Lingsma HF, van Tilborg AA, Zwarthoff EC. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clinical cancer research. 2013 Jul 10.

49. Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, Orntoft TF, Zwarthoff EC. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. The Journal of urology. 2013 May;189(5):1945-51.

50. van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC, Vergouwe Y, Zwarthoff EC, Steyerberg EW. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies. The Journal of urology. 2013 May;189(5):1676-81